ArticleLung2026
Defining Early Recurrence in Resectable Non-small Cell Lung Cancer Using Post-Recurrence Survival.
Article in Lung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to define a data-driven threshold in NSCLC using post-recurrence survival.
methodsPatients who underwent lung resection for stage I-IIIA NSCLC and experienced recurrence at a single institution from 2010 to 2021 were identified. Exclusion criteria included indeterminate N stage, M1 status, neoadjuvant therapy, and positive surgical margins. Time to recurrence was measured from surgery to recurrence, and post-recurrence survival from recurrence to death or last follow-up. Grid search and Kaplan-Meier analysis identified the time cut-point with the greatest survival difference, which was validated using multivariable Cox regression adjusted for age, race, tumor size, smoking history (pack-years), comorbodities, pathological N stage, histology, surgical procedure, and receipt of adjuvant therapy.
resultsA total of 227 patients met inclusion criteria, with 50% (114/227) female and 78% (177/227) white patients. The median age was 70 years (IQR 63-76), the tumor size was 2.6 cm (IQR 1.8-4.1), and time to recurrence was 17 months (IQR 9-30). Cut-point analysis identified 12 months as the threshold most strongly associated with survival after recurrence. Median post-recurrence survival was 14 months (IQR 4-32) versus 22 months (IQR 10-40) for patients that recurred within and after 12 months, respectively (log-rank p = 0.002). On multivariable analysis, the 12-month cut-point remained associated with survival after recurrence (HR 1.49, 95% CI 1.03-2.15, p = 0.03).
conclusionRecurrence within 12 months after resection of early-stage NSCLC is associated with worse post-recurrence survival, making this cutoff a useful indicator of early recurrence.
Indexed as
Identifiers
42747627What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.